254 related articles for article (PubMed ID: 32415406)
1. Management of Ibrutinib Toxicities: a Practical Guide.
Lasica M; Tam CS
Curr Hematol Malig Rep; 2020 Jun; 15(3):177-186. PubMed ID: 32415406
[TBL] [Abstract][Full Text] [Related]
2. Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
Molica S; Gianfelici V; Levato L
Expert Opin Emerg Drugs; 2020 Mar; 25(1):25-35. PubMed ID: 31996046
[No Abstract] [Full Text] [Related]
3. Ibrutinib dose modifications in the management of CLL.
Hardy-Abeloos C; Pinotti R; Gabrilove J
J Hematol Oncol; 2020 Jun; 13(1):66. PubMed ID: 32503582
[TBL] [Abstract][Full Text] [Related]
4. Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions.
Cho HJ; Baek DW; Kim J; Lee JM; Moon JH; Sohn SK
Expert Rev Hematol; 2021 Sep; 14(9):819-830. PubMed ID: 34375536
[TBL] [Abstract][Full Text] [Related]
5. Managing toxicities of Bruton tyrosine kinase inhibitors.
Lipsky A; Lamanna N
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):336-345. PubMed ID: 33275698
[TBL] [Abstract][Full Text] [Related]
6. Management of ibrutinib treatment in patients with B-cell malignancies: clinical practice in Portugal and multidisciplinary recommendations.
Carda JP; Santos L; Mariz JM; Monteiro P; Gonçalves HM; Raposo J; Gomes da Silva M
Hematology; 2021 Dec; 26(1):785-798. PubMed ID: 34605364
[TBL] [Abstract][Full Text] [Related]
7. Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.
de Weerdt I; Koopmans SM; Kater AP; van Gelder M
Haematologica; 2017 Oct; 102(10):1629-1639. PubMed ID: 28775119
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical.
Dong R; Yan Y; Zeng X; Lin N; Tan B
Drug Des Devel Ther; 2022; 16():3225-3239. PubMed ID: 36164415
[TBL] [Abstract][Full Text] [Related]
9. Haemorrhagic bullae and purpura associated with the Bruton tyrosine kinase inhibitor ibrutinib.
Steele L; George C; Cerio R; O'Toole EA
Clin Exp Dermatol; 2022 Feb; 47(2):488-490. PubMed ID: 34882824
[No Abstract] [Full Text] [Related]
10. Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections.
Maffei R; Maccaferri M; Arletti L; Fiorcari S; Benatti S; Potenza L; Luppi M; Marasca R
Blood Rev; 2020 Mar; 40():100635. PubMed ID: 31699465
[TBL] [Abstract][Full Text] [Related]
11. Management of adverse effects/toxicity of ibrutinib.
Paydas S
Crit Rev Oncol Hematol; 2019 Apr; 136():56-63. PubMed ID: 30878129
[TBL] [Abstract][Full Text] [Related]
12. Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond Ibrutinib.
Lasica M; Tam CS
Hematol Oncol Clin North Am; 2021 Aug; 35(4):761-773. PubMed ID: 34174985
[TBL] [Abstract][Full Text] [Related]
13. The Evolution of Targeted Therapies in Chronic Lymphocytic Leukaemia.
Gianfelici V; Levato L; Molica S
Curr Hematol Malig Rep; 2020 Aug; 15(4):343-349. PubMed ID: 32500413
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies.
Lama TG; Kyung D; O'Brien S
Expert Rev Hematol; 2020 Aug; 13(8):871-883. PubMed ID: 32673127
[TBL] [Abstract][Full Text] [Related]
15. Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.
Uminski K; Brown K; Bucher O; Hibbert I; Dhaliwal DH; Johnston JB; Geirnaert M; Dawe DE; Banerji V
Curr Oncol; 2019 Oct; 26(5):e610-e617. PubMed ID: 31708654
[TBL] [Abstract][Full Text] [Related]
16. Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.
Tang CPS; McMullen J; Tam C
Leuk Lymphoma; 2018 Jul; 59(7):1554-1564. PubMed ID: 28901789
[TBL] [Abstract][Full Text] [Related]
17. Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation.
Sestier M; Hillis C; Fraser G; Leong D
Curr Oncol Rep; 2021 Aug; 23(10):113. PubMed ID: 34342738
[TBL] [Abstract][Full Text] [Related]
18. Chronic lymphocytic leukaemia-associated insect bite-like reaction responding to ibrutinib, an immunomodulatory Bruton tyrosine kinase inhibitor.
Wimalachandra M; Basu TN; Salisbury J; Attard N; Calonje E; Patten PEM
Clin Exp Dermatol; 2021 Dec; 46(8):1569-1571. PubMed ID: 34028865
[No Abstract] [Full Text] [Related]
19. Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study.
Marchesini G; Nadali G; Facchinelli D; Candoni A; Cattaneo C; Laurenti L; Fanci R; Farina F; Lessi F; Visentin A; Marchesi F; Prezioso L; Spolzino A; Tisi MC; Trastulli F; Picardi M; Verga L; Dargenio M; Busca A; Pagano L;
Br J Haematol; 2021 Apr; 193(2):316-324. PubMed ID: 33058237
[TBL] [Abstract][Full Text] [Related]
20. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]